Here is the latest news from a line of potential corona virus vaccines in the world.
The pharmaceutical company AstraZeneca, which is a potential vaccine from the United States, has problems in its safety.
Therefore, the large-scale trial in the last phase has been temporarily postponed.
The delay was carried out after it was discovered that the disease had afflicted one of the trial participants.
In fact, the vaccine developed with the University of Oxford has been seen as one of the leading vaccine candidates against the corona virus.
The suspension of this trial ‘dims’ the prospect of a potential vaccine launch at the end of the year.
AstraZeneca said it had voluntarily stopped trials to allow an independent committee to review its security data.
It will work to expedite the review of these events, to minimize the potential impact on the trial schedule.
“This is a routine measure that must be taken whenever there is a potentially unexplained disease in one of the trials,” the company said in its statement Tuesday (9/8/2020), quoted by CNA.
However, the nature of the disease and when it occurred is not clearly stated.
The US Food and Drug Administration defines this as an adverse event.
Evidence suggests it may have something to do with the drug being tested.
According to a New York Times report citing someone with knowledge of the situation, a UK-based participant was found to have transverse myelitis.
It is an inflammatory syndrome that affects the spinal cord and is often triggered by a viral infection.
However, whether the disease is directly related to the AstraZeneca vaccine is unclear.
AstraZeneca also declined to comment on the report.
The suspension of trials has had an impact on other AstraZeneca vaccine trials.
It has even had an impact on clinical trials conducted by other vaccine makers, which have been looking for signs of a similar reaction.
The US National Institutes of Health, which provided funding for the AstraZeneca trial, declined to comment.
“In large trials, disease will occur by chance but must be reviewed independently for careful examination,” wrote the AstraZeneca statement.
Due to this incident, AstraZeneca’s shares fell more than 8 percent thereafter.
Meanwhile, shares of rival vaccine developers rose.
Moderna was up more than 4 percent and Pfizer was up less than 1 percent.
Nine of the leading US and European vaccine developers finally committed to enforcing safety standards, as well as scientific efficacy for their experimental vaccines on Tuesday.
These companies include AstraZeneca, Pfizer and GlaxoSmithKline.
They said they would uphold the integrity of the scientific process as they work toward the potential for submission of global regulations and approval of the first COVID-19 vaccine.
Apart from the United States, a potential vaccine from China is also responding to expert doubts about the safety of the vaccine.
China’s CanSino Biologics Inc defended the COVID-19 vaccine candidate, after experts doubted it.
This is related to the opinion of experts about the corona virus vaccine candidate that should not be followed “blindly” without adequate clinical trial data.
“Vaccine development is a practice-based science, and we shouldn’t follow the experts blindly,” said Zhu Tao, chief scientist, during a press conference, on Wednesday (9/9/2020), quoted from CNA.
Meanwhile, the Ad5-nCoV, which is still in its final stages of testing, has been approved for use in the Chinese military.